Would you like to get involved in Evidence Based Medicine?

Posted by Katriona O'Donoghue on June 15, 2016

We are looking for a (trainee) clinician to contribute to a systematic review involving the methodological quality appraisal of clinical practice guidelines in kidney transplantation. Specifically, you will evaluate and compare the quality of 20 clinical practice guidelines in kidney transplantation using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument. The estimated time commitment is around 40 -50 hours. You will learn skills to appraise clinical practice guidelines and you will receive a publication as a result.  For more information on the protocol, please visit Prospero here.

If you are interested in becoming involved, please e-mail Katriona O’Donoghue at [email protected]





June 2016 Transplant Trial Watch is now online

Posted by Simon Knight on June 3, 2016

The June 2016 Transplant Trial Watch is now available.

This month, the trial watch includes systematic reviews of quality of life reporting in renal transplant trials and extended criteria donors, as well as an analysis of wound complications with everolimus following cardiac transplantation.





How can we improve the Transplant Library?

Posted by Simon Knight on May 5, 2016

We are seeking feedback from users of the Transplant Library, to help us to improve the experience for our many users. We would be very grateful if current users would take the time to complete a short survey about the library.

The survey can be accessed here.





May 2016 Transplant Trial Watch now available

Posted by Simon Knight on April 29, 2016

The May 2016 Transplant Trial Watch is now available online and via our app for iPhone, iPad and Android.

This months new trials include long-term follow-up from the Spare the Nephron trial, methods for promoting organ donation and mobile medical apps for encouraging sun protection behaviour.





Facial Transplantation Moves Forward

Posted by Peter Morris on April 14, 2016

This is quite a remarkable achievement in that the patient, a volunteer fire-fighter aged 41, had suffered severe burns across his entire face including the loss of eyelids, ears, lips, most of his nose and the entire scalp during a rescue search in a burning home in 2010. He had had some 80 reconstructive procedures on his face since the injury and all this reconstruction had to be excised at the time of  the transplant. Dr. Rodriquez, a surgeon at NYU Langone, with a team of some 100 colleagues and assistants, found a suitable donor and successfully carried out the donor operation and the transplant in adjoining theaters.  However, what is unusual in this particular case, among the 37 cases of facial transplant carried out worldwide, was the use of 3-D modelling to enable a good fit with the patient’s skeleton as some of the skeleton of the patients face had to be replaced or augmented in addition to the soft tissues. He still had his eyesight intact and so they were able to transplant the face with eyelids and relevant muscles and both ears in April 2014. This was indeed a tour de force. At the time of the report there had been no episodes of acute rejection and the functional result is impressive.

Dr Rodriquez is a graduate of the Medical College of Virginia and received his plastic surgeon training at the Johns Hopkins before moving to NYU Langone. He had performed a face transplant earlier in Baltimore before his move to NYU. The cost of the procedure and all related care was estimated to be around $1 million dollars. This is definitely a further step forward in establishing facial transplantation as an acceptable procedure in the right centre, but it remains an experimental procedure.

Bulletin of the American College of Surgeons, April 2016.





Hesperis course – special rate ends Thursday 31/3

Posted by Liset Pengel on March 29, 2016

Hesperis016 1180x350

This highly-recommended course covers the whole field of basic transplantation medicine and surgery. State-of-the-art lectures are combined with interactive workshops in small groups and sport educational games. Educators and delegates will have ample opportunity to meet, socialise and share ideas.

For more details or to register, go to http://bit.ly/Hesperis2016

The exciting programme includes:

  • HESPERIS GAMES – who will be the Best Transplant Team for HC2016?
  • Break out sessions in the afternoons
  • Special moments to meet, build your network, share and prepare relevant questions for the “Big Players”
  • Case presentations – submitted by the participants

 





Paul Terasaki Memorial Service

Posted by Peter Morris on March 14, 2016

A Memorial Service was held on March 6th at Royce Hall at UCLA. It was a marvellous service in memory of a great pioneer in organ transplantation and the tributes were all memorable. Some 1000 people attended. The service started with an opening song by the opera singer, Miss Lova Hyatt, ‘Amazing Grace’, and then the Master of Ceremonies, Fred Katayama, a nephew of Paul Terasaki, introduced the various speakers.  The programme started with Paul’s Methodist Minister, Gary Oba, giving the Invocation, and then a number of speakers spoke about his contributions to science and organ transplantation.  These included an address by the UCLA Chancellor Gene Block, a video from Tom Starzl, who is no longer able to travel, and then Walter Bodmer, Peter Morris, Mike Cecka, and one or two other friends and colleagues particularly from the Japanese American association. It was, indeed, a fitting Memorial Service to Paul Terasaki and was followed by a reception in the grounds outside Royce Hall.  All in all a great occasion, and a celebration of a great man’s career, not only as a scientist but also as a philanthropist.





March 2016 Transplant Trial Watch now available

Posted by Simon Knight on March 1, 2016

The March edition of the Transplant Trial Watch is now available via our website and the Trial Watch App.

This month’s trials include the effect of Omega-3 on hepatic regeneration after live liver donation, prophylactic azithromycin after lung transplantation, and the consequences of complete tacrolimus withdrawal in renal transplant recipients.





SONG-TX – developing a core outcome set for renal transplantation

Posted by Simon Knight on February 17, 2016

Many clinical trials have been conducted in kidney transplantation but a wide variety of different outcomes are reported and in different ways, and it is unclear whether they are important to people who have received a kidney transplant. There has been no agreement about what are the most important outcomes to measure and report in studies for kidney transplant recipients. Variability in outcome reporting makes interpretation, comparison and combination of studies in meta-analysis challenging.

The Centre for Evidence in Transplantation is pleased to announce that it is supporting an initiative to create a set of standardised, core outcomes for use in renal transplant trials, audits and registries – the SONG-TX initiative. More details about the project can be found on the project website. The process involves three phases:

  1. a systematic review to identify outcomes that have been reported in trials in kidney transplantation
  2. a three-round Delphi survey with stakeholder groups to distill and generate a prioritised list of core outcomes
  3. a consensus workshop to establish a core outcome set for kidney transplantation trials.

Registration for the first Delphi survey is now open. To take part, register your interest here.





Top Ten Priorities in Kidney Transplant research from the Kidney Transplant PSP

Posted by Simon Knight on February 4, 2016

On the 3rd February 2016, a group of 20 kidney transplant recipients, donors and professionals took part in a consensus workshop at the Royal College of Surgeons of England, in London. The group considered the top 25 ranked treatment uncertainties from the PSP prioritisation survey, and after much lively debate agreed a top ten list of priorities for the future of research in kidney transplantation.

The top ten priorities agreed by the group were as follows:

  • What is the best way to treat vascular or antibody-mediated acute rejection?
  • How can immunosuppression be personalised to the individual patients to improve the results of transplantation?
  • How can we prevent sensitisation in patients with a failing transplant, to improve their chances of another successful transplant (e.g. removal of the transplant, withdrawal of immunosuppressive medicines or continuation of these medicines?)
  • Can we improve monitoring of the level of immunosuppression to achieve better balance between risk of rejection and side effects? (e.g. T-cell or B-cell ELISPOT, point-of-care tacrolimus monitoring, MMF monitoring)
  • How can we improve transplant rates in highly sensitised patients?
  • What are the long-term health risks to the living kidney donor?
  • How can we encourage tolerance to the transplant to prevent or reduce the need for immunosuppression? (e.g. by use of T-regulatory cells, induction of haemoxygenase 1)
  • What is the best combination of immunosuppressive drugs following kidney transplantation? (e.g. azathioprine or mycophenolate, belatacept, generic or proprietary (brand-name) drugs)
  • What techniques to preserve, condition and transport the kidney before transplantation allow increased preservation times and/or improve results? (e.g. machine perfusion, normothermic reconditioning, addition of agents to the perfusate)
  • Can bioengineered organs be developed to be as safe as human-to-human transplants? How can this be achieved?

We would like to extend a big thank-you to all those who took part in the PSP process, including the steering group, all those who responded to the surveys and the group who attended the final workshop.

For more information on the project, please visit the PSP website.





Next Page »